报告期内，集团录得净亏损人民币220万元，较截至2024年6月30日止六个月的亏损人民币5780万元显著 减少，该减少主要是由于(i)收入及毛利稳定增长；(ii)通过持续优化资源配置、积极管控各项费用等措 施进一步提升运营效率；及(iii)集团的联营公司4C Medical完成D轮融资后，视作出售其股权所产生的收 益。 格隆汇8月29日丨心通医疗-B(02160.HK)发布公告，截至2025年6月30日止六个月，集团录得收入人民币 2.291亿元，同比增加2.7%，主要是由于报告期内，VitaFlow Liberty®及Alwide®Plus在全球商业化的持 续推进，促进了集团的海外收入较2024年同期快速增长235.3%。此外，于报告期内，集团的 AnchorMan®左心耳封堵系统及AnchorMan®左心耳导引系统在中国的商业化进展稳步推进，且随后在 欧洲实现商业化，亦为集团带来新增收入贡献。 ...

公告称，收入增加主要是由于于报告期内，集团的VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系 统在全球商业化方面的持续推进促进了海外收入的大幅增长;及集团的AnchorMan®左心耳封堵系统及 AnchorMan®左心耳导引系统在中国和海外的商业化进展稳步推进。 智通财经APP讯，心通医疗-B(02160)发布截至2025年6月30日止6个月的中期业绩，该集团取得收入2.29 亿元，同比增加2.67%;公司权益股东应占亏损216.3万元，同比减少96.17%;每股基本亏损0.09分。 ...

Core Insights - The article highlights the recent acquisition by Heart通医疗 of the remaining 49% stake in Shanghai Zhaoxin, making it a wholly-owned subsidiary, with a total acquisition cost of RMB 170 million [1][2]. Company Overview - Heart通医疗, established in 2009 and officially registered in 2015, focuses on innovative medical devices for structural heart diseases, with its headquarters in Shanghai and listed on the Hong Kong Stock Exchange in 2021 [2]. - The company emphasizes research and innovation, developing a comprehensive range of transcatheter and surgical solutions for structural heart diseases, including products for transcatheter aortic valve implantation (TAVI) [2]. Market Performance - Shanghai Zhaoxin specializes in left atrial appendage-related medical devices, with its core product, the AnchorMan left atrial appendage occlusion system, receiving NMPA approval for market entry in January 2024 [5][6]. - The TAVI series products of Heart通医疗 are already in over 650 hospitals across China, and the company has expanded its international presence to nearly a hundred hospitals in countries like Argentina, Colombia, and Switzerland [4]. Product Development - The AnchorMan left atrial appendage occlusion system has shown promising clinical results, achieving a 98.1% clinical success rate and a 100% left atrial appendage occlusion success rate in a one-year follow-up study [7].